Following a survey of 80 U.S. cardiologists who currently treat hypertrophic cardiomyopathy, or HCM, patients, Guggenheim analyst Etzer Darout said he believes the design of MyoKardia's EXPLORER trial sufficiently mitigates risk of cardiovascular safety. Also, the cardiologists surveyed were comfortable with the likelihood of a positive efficacy outcome, which supports his "high conviction" that the trial will show a clinically meaningful benefit from mavacamten, Darout tells investors. He reiterated his Buy rating on MyoKardia shares following the survey.